Jazz Pharmaceuticals JAZZ Total Oncology — Total revenues
Discontinued — last reported Q4 '25
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's total oncology — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's total oncology — total revenues?
- Jazz Pharmaceuticals (JAZZ) reported total oncology — total revenues of $337.28M in Q4 2025.
- How has Jazz Pharmaceuticals's total oncology — total revenues changed year-over-year?
- Jazz Pharmaceuticals's total oncology — total revenues increased by 15.6% year-over-year, from $291.76M to $337.28M.
- What is the long-term trend for Jazz Pharmaceuticals's total oncology — total revenues?
- Over 3 years (2022 to 2025), Jazz Pharmaceuticals's total oncology — total revenues has grown at a 8.9% compound annual growth rate (CAGR), from $873.84M to $1.13B.
- What does total oncology — total revenues mean?
- The total sales revenue generated by the company's oncology drug portfolio.
- How do you interpret total oncology — total revenues?
- An increase indicates successful commercial execution, market penetration, or the effective launch of new oncology therapies, while a decrease may signal competitive pressure, patent expirations, or declining demand for specific cancer treatments.
- How does total oncology — total revenues compare across companies?
- Comparable to oncology-specific revenue segments reported by other diversified biopharmaceutical companies, often benchmarked against overall portfolio growth rates and market share within specific cancer indications.